FibroGen pays SEC $1.2M over allegations former exec ‘reverse engineered’ roxadustat data
FibroGen has agreed to pay $1.25 million to the Securities and Exchange Commission (SEC) to address allegations that the biopharma’s former chief medical officer manipulated data for the anemia drug…